Clinical and Experimental Pediatrics

대한소아청소년과학회 (The Korean Pediatric Society)
권호 표지
DOI QR코드

DOI QR Code

Usefulness of serum cystatin C to determine the dose of vancomycin in neonate

  • Shin, Jeong Eun (Department of Pediatrics, Yonsei University College of Medicine) ;
  • Lee, Soon Min (Department of Pediatrics, Yonsei University College of Medicine) ;
  • Eun, Ho Seon (Department of Pediatrics, Yonsei University College of Medicine) ;
  • Park, Min Soo (Department of Pediatrics, Yonsei University College of Medicine) ;
  • Park, Kook In (Department of Pediatrics, Yonsei University College of Medicine) ;
  • Namgung, Ran (Department of Pediatrics, Yonsei University College of Medicine)
  • 투고 : 2014.08.26
  • 심사 : 2014.11.07
  • 발행 : 2015.11.15
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: The vancomycin dosage regimen is regularly modified according to the patient's glomerular filtration rate (GFR). In the present study, we aimed to assess the usefulness of serum cystatin C (Cys-C) concentration, compared with serum creatinine (SCr) concentration, for predicting vancomycin clearance (CLvcm) in neonates. Methods: We retrospectively analyzed the laboratory data of 50 term neonates who were admitted to the neonatal intensive care unit and received intravenous vancomycin, and assessed the pharmacokinetic profiles. Creatinine clearance (CLcr) and GFR based on Cys-C (GFRcys-c) were estimated using the Schwartz and Larsson formulas, respectively. Results: The mean CLvcm (${\pm}$standard deviation) was $74.52{\pm}31.17L/hr$, the volume of distribution of vancomycin was $0.67{\pm}0.14L$, and vancomycin half-life was $9.16{\pm}17.42hours$. The SCr was $0.46{\pm}0.25mg/dL$ and serum Cys-C was $1.43{\pm}0.34mg/L$. The peak and trough concentrations of vancomycin were $24.65{\pm}14.84$ and $8.10{\pm}5.35mcg/mL$, respectively. The calculated GFR based on serum creatinine concentration (GFR-Cr) and GFRcys-c were $70.2{\pm}9.45$ and $63.6{\pm}30.18mL/min$, respectively. The correlation constant for CLvcm and the reciprocal of Cys-C (0.479, P=0.001) was significantly higher than that for CLvcm and the reciprocal of SCr (0.286, P=0.044). GFRcys-c was strongly correlated with CLvcm (P=0.001), and the correlation constant was significantly higher than that for CLvcm and CLcr (0.496, P=0.001). Linear regression analysis showed that only GFRcys-c was independently and positively correlated with CLvcm (F=41.9, P<0.001). Conclusion: The use of serum Cys-C as a marker of CLvcm could be beneficial for more reliable predictions of serum vancomycin concentrations, particularly in neonates.

키워드

참고문헌

  1. Appelbaum PC. Microbiology of antibiotic resistance in Staphylococcus aureus. Clin Infect Dis 2007;45 Suppl 3:S165-70. https://doi.org/10.1086/519474
  2. Iwamoto T, Kagawa Y, Kojima M. Clinical efficacy of therapeutic drug monitoring in patients receiving vancomycin. Biol Pharm Bull 2003;26:876-9. https://doi.org/10.1248/bpb.26.876
  3. de Hoog M, Mouton JW, van den Anker JN. Vancomycin: pharmacokinetics and administration regimens in neonates. Clin Pharmacokinet 2004;43:417-40. https://doi.org/10.2165/00003088-200443070-00001
  4. Okamoto G, Sakamoto T, Kimura M, Ukishima Y, Sonoda A, Mori N, et al. Serum cystatin C as a better marker of vancomycin clearance than serum creatinine in elderly patients. Clin Biochem 2007;40:485-90. https://doi.org/10.1016/j.clinbiochem.2007.01.008
  5. Laterza OF, Price CP, Scott MG. Cystatin C: an improved estimator of glomerular filtration rate? Clin Chem 2002;48:699-707.
  6. Simonsen O, Grubb A, Thysell H. The blood serum concentration of cystatin C (gamma-trace) as a measure of the glomerular filtration rate. Scand J Clin Lab Invest 1985;45:97-101. https://doi.org/10.3109/00365518509160980
  7. Roos JF, Doust J, Tett SE, Kirkpatrick CM. Diagnostic accuracy of cystatin C compared to serum creatinine for the estimation of renal dysfunction in adults and children: a meta-analysis. Clin Biochem 2007;40:383-91. https://doi.org/10.1016/j.clinbiochem.2006.10.026
  8. Larsson A, Malm J, Grubb A, Hansson LO. Calculation of glomerular filtration rate expressed in mL/min from plasma cystatin C values in mg/L. Scand J Clin Lab Invest 2004;64:25-30. https://doi.org/10.1080/00365510410003723
  9. Schwartz GJ, Haycock GB, Edelmann CM Jr, Spitzer A. A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 1976;58:259-63.
  10. Oudin C, Vialet R, Boulamery A, Martin C, Simon N. Vancomycin prescription in neonates and young infants: toward a simplified dosage. Arch Dis Child Fetal Neonatal Ed 2011;96:F365-70. https://doi.org/10.1136/adc.2010.196402
  11. Kimura T, Sunakawa K, Matsuura N, Kubo H, Shimada S, Yago K. Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates. Antimicrob Agents Chemother 2004;48:1159-67. https://doi.org/10.1128/AAC.48.4.1159-1167.2004
  12. Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother 1990;25:679-87. https://doi.org/10.1093/jac/25.4.679
  13. Schumacher GE, Barr JT. Using population-based serum drug concentration cutoff values to predict toxicity: test performance and limitations compared with Bayesian interpretation. Clin Pharm 1990;9:788-96.
  14. Leonard MB, Koren G, Stevenson DK, Prober CG. Vancomycin pharmacokinetics in very low birth weight neonates. Pediatr Infect Dis J 1989;8:282-6.
  15. Stevens LA, Schmid CH, Greene T, Zhang YL, Beck GJ, Froissart M, et al. Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/ min/1.73 m2. Am J Kidney Dis 2010;56:486-95. https://doi.org/10.1053/j.ajkd.2010.03.026
  16. Skali H, Uno H, Levey AS, Inker LA, Pfeffer MA, Solomon SD. Prognostic assessment of estimated glomerular filtration rate by the new Chronic Kidney Disease Epidemiology Collaboration equation in comparison with the Modification of Diet in Renal Disease Study equation. Am Heart J 2011;162:548-54. https://doi.org/10.1016/j.ahj.2011.06.006
  17. Stevens LA, Li S, Kurella Tamura M, Chen SC, Vassalotti JA, Norris KC, et al. Comparison of the CKD Epidemiology Collaboration (CKD-EPI) and Modification of Diet in Renal Disease (MDRD) study equations: risk factors for and complications of CKD and mortality in the Kidney Early Evaluation Program (KEEP). Am J Kidney Dis 2011;57(3 Suppl 2):S9-16. https://doi.org/10.1053/j.ajkd.2010.11.007
  18. Matsushita K, Tonelli M, Lloyd A, Levey AS, Coresh J, Hemmelgarn BR, et al. Clinical risk implications of the CKD Epidemiology Collaboration (CKD-EPI) equation compared with the Modification of Diet in Renal Disease (MDRD) Study equation for estimated GFR. Am J Kidney Dis 2012;60:241-9. https://doi.org/10.1053/j.ajkd.2012.03.016
  19. Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 2010;55:622-7. https://doi.org/10.1053/j.ajkd.2010.02.337
  20. Gaspari F, Ruggenenti P, Porrini E, Motterlini N, Cannata A, Carrara F, et al. The GFR and GFR decline cannot be accurately estimated in type 2 diabetics. Kidney Int 2013;84:164-73. https://doi.org/10.1038/ki.2013.47
  21. Zhang M, Cao X, Cai G, Wu D, Wei R, Yuan X, et al. Clinical evaluation of serum cystatin C and creatinine in patients with chronic kidney disease: a meta-analysis. J Int Med Res 2013;41:944-55. https://doi.org/10.1177/0300060513480922
  22. Chung JY, Jin SJ, Yoon JH, Song YG. Serum cystatin C is a major predictor of vancomycin clearance in a population pharmacokinetic analysis of patients with normal serum creatinine concentrations. J Korean Med Sci 2013;28:48-54. https://doi.org/10.3346/jkms.2013.28.1.48
  23. Randers E, Erlandsen EJ. Serum cystatin C as an endogenous marker of the renal function: a review. Clin Chem Lab Med 1999;37:389-95.
  24. Hermida J, Tutor JC. Serum cystatin C for the prediction of glomerular filtration rate with regard to the dose adjustment of amikacin, gentamicin, tobramycin, and vancomycin. Ther Drug Monit 2006;28:326-31. https://doi.org/10.1097/01.ftd.0000211805.89440.3d

피인용 문헌

  1. Comparison of the Predictive Performance Between Cystatin C and Serum Creatinine by Vancomycin via a Population Pharmacokinetic Models: A Prospective Study in a Chinese Population vol.45, pp.1, 2015, https://doi.org/10.1007/s13318-019-00578-4
  2. Is Cystatin C Good Enough as a Biomarker for Vancomycin Dosing: A Pharmacokinetic Perspective vol.45, pp.1, 2015, https://doi.org/10.1007/s13318-019-00587-3
  3. A Meta-Analysis on the Performance of Cystatin C- versus Creatinine-based eGFR Equations in Predicting Vancomycin Clearance vol.35, pp.37, 2015, https://doi.org/10.3346/jkms.2020.35.e306